Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22110450 | 0.87 | CHRM3 (0.49) | SLC18A2MAPK1CHRM3CHRNB2CHRNA5 | |
| SCHEMBL22110286 | 0.87 | CHRM3 (0.49) | SLC18A2MAPK1CHRM3CHRNB2CHRNA5 | |
| SCHEMBL22110310 | 0.80 | ACE2 (0.36) | SLC18A2MAPK1LTA4HCHRNB2CHRNA5 | |
| SCHEMBL22110352 | 0.80 | KDM4E (0.48) | SLC18A2CHRM3LTA4H | |
| SCHEMBL2603270 | 0.79 | SLC18A2 (0.50) | SLC18A2CHRM3 | |
| SCHEMBL13995045 | 0.79 | SLC18A2 (0.50) | SLC18A2CHRM3 | |
| SCHEMBL8806151 | 0.79 | ADRA2A (0.52) | CHRM3LTA4HCHRNB2CHRNA5CHRNA7 | |
| SCHEMBL3987832 | 0.77 | CHRM3 (0.51) | CHRM3 | |
| SCHEMBL2603288 | 0.75 | SLC18A2 (0.49) | SLC18A2 | |
| SCHEMBL26724276 | 0.73 | TSHR (0.34) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535627-B2 | Pyrimidine derivative compound, pharmaceutically acceptable salt thereof, preparation process thereof, and pharmaceutical composition using the same | SPARK BIOPHARMA, INC. (KR) | 2022-12-27 | — | — | US | disclosed |
| US-20200190099-A1 | NOVEL PYRIMIDINE DERIVATIVE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION PROCESS THEREOF, AND PHARMACEUTICAL COMPOSITION USING THE SAME | SPARK BIOPHARM, INC. (KR) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535627-B2 | Pyrimidine derivative compound, pharmaceutically acceptable salt thereof, preparation process thereof, and pharmaceutical composition using the same | DPYD, TYMP, NUDT1 | SLC18A2 1540/4885MAPK1 3446/4885CHRM3 4777/4885 |
| US-20200190099-A1 | NOVEL PYRIMIDINE DERIVATIVE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION PROCESS THEREOF, AND PHARMACEUTICAL COMPOSITION USING THE SAME | DPYD, NUDT1, NUDT5 | SLC18A2 1464/4885MAPK1 3371/4885CHRM3 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.